Corixa Corporation clinical trials
Acquired by GlaxoSmithKline
The registry lists 8 studies whose lead sponsor is Corixa Corporation. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 6, 2006.
- 8studies on the registry
- 0open to participants now
What it is testing
The drugs Corixa Corporation’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 6
All 8 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed113%
- Status unknown or other788%
Registry sponsor names on this page
- Corixa Corporation8 studies
Something wrong with this grouping? Tell us on the GlaxoSmithKline page.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. All GlaxoSmithKline studies →
- Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung CancerStatus unknownNCT00062907Phase 1
Sponsor listed in the registry: Corixa Corporation · Corixa Corporation — acquired company within the GlaxoSmithKline group
- A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's LymphomaStatus unknownNCT00078598Phase 3
Sponsor listed in the registry: Corixa Corporation · Corixa Corporation — acquired company within the GlaxoSmithKline group
- Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic LeukemiaStatus unknownNCT00022880Phase 1
Sponsor listed in the registry: Corixa Corporation · Corixa Corporation — acquired company within the GlaxoSmithKline group
- Expanded Access Study of Iodine-131 Anti-B1 AntibodyStatus unknownNCT00022958Not applicable
Sponsor listed in the registry: Corixa Corporation · Corixa Corporation — acquired company within the GlaxoSmithKline group
- Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOPStatus unknownNCT00022932Phase 2
Sponsor listed in the registry: Corixa Corporation · Corixa Corporation — acquired company within the GlaxoSmithKline group
- Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow InvolvementStatus unknownNCT00022906Phase 1
Sponsor listed in the registry: Corixa Corporation · Corixa Corporation — acquired company within the GlaxoSmithKline group
- Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's LymphomaStatus unknownNCT00022893Not applicable
Sponsor listed in the registry: Corixa Corporation · Corixa Corporation — acquired company within the GlaxoSmithKline group
- Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell LymphomaCompletedNCT00022945Phase 2
Sponsor listed in the registry: Corixa Corporation · Corixa Corporation — acquired company within the GlaxoSmithKline group